Multicenter cross-sectional study of patients with rheumatoid arthritis in Greece: Results from a cohort of 2.491 patients
Ημερομηνία
2018Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Aim of the study: To evaluate the current disease characteristics, treatment and comorbidities of rheumatoid arthritis (RA) in Greece. Methods: Multicenter, cross-sectional study with a 9-month recruitment period between 2015 and 2016. Demographics, disease characteristics, treatment and comorbidities were collected via a web-based platform. Results:2.491 RA patients were recruited: 96% from tertiary referral centers, 79% were females with a mean age of 63.1 years and disease duration of 9.9 years. Fifty-two percent were rheumatoid factor and/or anti-CCP positive, while 41% had erosive disease. Regarding treatment, 82% were on conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), 42% on biologic DMARDs (TNFi: 22%, non-TNFi: 20%) and 40% on corticosteroids (mean daily dose: 5.2 mg). Despite therapy, 36% of patients had moderate and 12% high disease activity. The most frequent comorbidities were hypertension (42%), hyperlipidemia (33%), osteoporosis (29%), diabetes mellitus (15%) and depression (12%). Latent tuberculosis infection (positive tuberculin skin test or interferon gamma release assay) was diagnosed in 13 and 15.3% of patients, respectively. Regarding chronic viral infections, 6.2% had history of herpes zoster while 2% and 0.7% had chronic hepatitis B and C virus infection, respectively. A history of serious infection was documented in 9.6%. Only 36% and 52% of the participants had ever been vaccinated against pneumococcus and influenza virus, respectively. Conclusion: This is one of the largest epidemiologic studies providing valuable data regarding the current RA characteristics in Greece. Half of patients were seropositive but despite therapy, half displayed residual disease activity, while preventive vaccination was limited. © Thomas K, Lazarini A, Kaltsonoudis E, Drosos AA, Papalopoulos I, Sidiropoulos P, Katsimbri P, Boumpas D, Tsatsani P, Gazi S, Fragkiadaki K, Tektonidou M, Sfikakis P P, Pantazi L, Boki K A, Grika E P, Vlachoyiannopoulos P G, Karagianni K, Sakkas L I, Dimitroulas T, Garyfallos A, Kassimos D, Gerasimos E, Iliopoulos A, Areti A, Georganas C, Melissaropoulos K, Georgiou P, Vounotrypidis P, Ntelis K, Mavragani C P, Bournazos I, Katsifis G, Mavrommatis C, Kitas G D, Vassilopoulos D.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Direct oral anticoagulant-vs Vitamin K antagonist-related nontraumatic intracerebral hemorrhage
Tsivgoulis G., Lioutas V.-A., Varelas P., Katsanos A.H., Goyal N., Mikulik R., Barlinn K., Krogias C., Sharma V.K., Vadikolias K., Dardiotis E., Karapanayiotides T., Pappa A., Zompola C., Triantafyllou S., Kargiotis O., Ioakeimidis M., Giannopoulos S., Kerro A., Tsantes A., Mehta C., Jones M., Schroeder C., Norton C., Bonakis A., Chang J., Alexandrov A.W., Mitsias P., Alexandrov A.V. (2017)Objective: To compare the neuroimaging profile and clinical outcomes among patients with intracerebral hemorrhage (ICH) related to use of vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) for nonvalvular ... -
Clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the collaborative ocular tuberculosis study (COTS)-1
Agrawal R., Gunasekeran D.V., Grant R., Agarwal A., Kon O.M., Nguyen Q.D., Pavesio C., Gupta V., Gupta B., Aggarwal K., Murthy S.L., Westcott M., Phaik C.S., McCluskey P., Ling H.S., Teoh S., Cimino L., Biswas J., Narain S., Agarwal M., Mahendradas P., Khairallah M., Jones N., Tugal-Tutkun I., Babu K., Basu S., Carreño E., Lee R., Al-Dhibi H., Bodaghi B., Invernizzi A., Goldstein D.A., Herbort C.P., Barisani T., González-López J.J., Androudi S., Bansal R., Moharana B., Mahajan S., Esposti S., Tasiopoulou A., Nadarajah S., Agarwal M., Abraham S., Vala R., Singh R., Sharma A., Sharma K., Zierhut M., Raje D., Cunningham E., Kempen J., Collaborative Ocular Tuberculosis Study (COTS)-1 Study Group (2017)IMPORTANCE Eradication of systemic tuberculosis (TB) has been limited by neglected populations and the HIV pandemic. Whereas ocular TB often presents as uveitis without any prior evidence of systemic TB, the existing ... -
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
Fountzilas G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., Lakis S., Bobos M., Poulios C., Sotiropoulou M., Lyberopoulou A., Gogas H., Pentheroudakis G., Pectasides D., Koutras A., Christodoulou C., Papandreou C., Samantas E., Papakostas P., Kosmidis P., Bafaloukos D., Karanikiotis C., Dimopoulos M.-A., Kotoula V. (2016)Background: We investigated the impact of PIK3CA and TP53 mutations and p53 protein status on the outcome of patients who had been treated with adjuvant anthracycline-taxane chemotherapy within clinical trials in the pre- ...